Multiple Sclerosis: Reprogramming the Immune Repertoire with Alemtuzumab in MS

Overview

Journal Nat Rev Neurol

Specialty Neurology

Date 2013 Jan 30

PMID 23358486

Citations 28

Authors

Heinz Wiendl

Bernd Kieseier

Affiliations

Soon will be listed here.

Abstract

Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.

Citing Articles

Influence of Pre-Analytic Conditions on Quantity of Lymphocytes.

Proschmann U, Amirkhiz P, Andres P, Haase R, Inojosa H, Ziemssen T Int J Mol Sci. 2023; 24(17).

PMID: 37686285 PMC: 10487632. DOI: 10.3390/ijms241713479.

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study.

Achini-Gutzwiller F, Schilham M, von Asmuth E, Jansen-Hoogendijk A, Jol-van der Zijde C, Van Tol M Blood Adv. 2023; 7(16):4462-4474.

PMID: 37285798 PMC: 10440472. DOI: 10.1182/bloodadvances.2022009051.

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.

Ruck T, Barman S, Schulte-Mecklenbeck A, Pfeuffer S, Steffen F, Nelke C Brain. 2022; 145(5):1711-1725.

PMID: 35661859 PMC: 9166548. DOI: 10.1093/brain/awac064.

Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients.

Bath N, Djamali A, Parajuli S, Mandelbrot D, Leverson G, Hidalgo L Kidney360. 2022; 1(12):1407-1418.

PMID: 35372884 PMC: 8815535. DOI: 10.34067/KID.0000122020.

Comparison of the antibacterial activity of Australian Terminalia spp. extracts against Klebsiella pneumoniae: a potential treatment for ankylosing spondylitis.

Courtney R, Cock I Inflammopharmacology. 2022; 30(1):207-223.

PMID: 34989930 DOI: 10.1007/s10787-021-00914-8.

References

Jones J, Phuah C, Cox A, Thompson S, Ban M, Shawcross J . IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009; 119(7):2052-61. PMC: 2701868. DOI: 10.1172/JCI37878. View

Cohen J, Coles A, Arnold D, Confavreux C, Fox E, Hartung H . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856):1819-28. DOI: 10.1016/S0140-6736(12)61769-3. View

Walsh M, Chaudhry A, Jayne D . Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis. 2007; 67(9):1322-7. DOI: 10.1136/ard.2007.081661. View

Coles A, Compston D, Selmaj K, Lake S, Moran S, Margolin D . Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008; 359(17):1786-801. DOI: 10.1056/NEJMoa0802670. View

Klotz L, Meuth S, Wiendl H . Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol. 2011; 142(1):25-30. DOI: 10.1016/j.clim.2011.04.006. View